The patent application WO2011013785, related to delgocitinib, was published by delgocitinib. This application details methods of treating inflammatory skin conditions, specifically atopic dermatitis, using delgocitinib. The treatment involves administering a Janus kinase (JAK) inhibitor, such as delgocitinib, to a subject in need thereof. [1]
What is Delgocitinib?
Delgocitinib is an orally available small molecule inhibitor targeting Janus kinases (JAKs). Specifically, it inhibits JAK1, JAK2, JAK3, and TYK2. By inhibiting these enzymes, delgocitinib modulates the signaling pathways of various cytokines involved in immune responses and inflammation, making it a therapeutic target for autoimmune and inflammatory diseases. [1]
How is Delgocitinib Used for Atopic Dermatitis?
Patent application WO2011013785 describes methods for treating atopic dermatitis with delgocitinib. The treatment typically involves administering a pharmaceutical composition containing delgocitinib. This approach aims to reduce inflammation and alleviate the symptoms associated with atopic dermatitis. [1]
What Other Conditions Might Delgocitinib Treat?
While WO2011013785 specifically addresses atopic dermatitis, delgocitinib's mechanism of action as a pan-JAK inhibitor suggests potential applications in other inflammatory and autoimmune conditions. Diseases driven by cytokine dysregulation, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are often explored with JAK inhibitors. [1]
When Does Patent Protection for Delgocitinib Expire?
Information regarding the specific patent expiry dates for delgocitinib is not detailed in the provided patent application WO2011013785. Patent protection timelines are complex and depend on various factors including the original filing date, any granted patents, and potential extensions due to regulatory delays. Resources like DrugPatentWatch.com track such information to provide detailed patent landscapes for pharmaceuticals. [2]
Who Developed Delgocitinib?
The patent application WO2011013785 lists delgocitinib as an applicant. Further research would be needed to identify the specific company or research institution that originally developed delgocitinib and its associated patent family. [1]
What are the Risks Associated with JAK Inhibitors?
JAK inhibitors, including delgocitinib, carry potential risks that have been identified through clinical trials and post-marketing surveillance. These can include an increased risk of serious infections, cardiovascular events (such as heart attack and stroke), thrombosis (blood clots), and certain types of cancer. Regulatory bodies often issue warnings and recommendations regarding these risks, which are important considerations for both patients and healthcare providers. [3]
---
Sources
1. WO2011013785 - Google Patents
2. DrugPatentWatch.com
3. FDA Drug Safety Communication